PD19-08 RADIOFREQUENCY-INDUCED THERMO-CHEMOTHERAPY EFFECT (RITE) PLUS MITOMYCIN VERSUS A SECOND COURSE OF BACILLUS CALMETTE-GUÉRIN (BCG) OR INSTITUTIONAL STANDARD IN PATIENTS WITH RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWING INDUCTION OR MAINTENANCE BCG THERAPY (HYMN): A OPEN-LABEL, MULTICENTRE, PHASE III RANDOMISED CONTROLLED TRIAL

Open Label ◽

Multicentre Phase ◽

Bcg Therapy ◽

Muscle Invasive ◽

Radiofrequency-induced thermo-chemotherapy effect plus mitomycin versus a second course of bacillus Calmette-Guérin (BCG) or institutional standard in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance BCG therapy (HYMN): A phase III, open-label, randomised controlled trial

European Urology Supplements ◽

10.1016/s1569-9056(17)30720-0 ◽

2017 ◽

Vol 16 (3) ◽

pp. e1156-e1157

Author(s):

W.S. Tan ◽

L. Buckley ◽

A. Devall ◽

L. Loubière ◽

A. Pope ◽

...

Keyword(s):

Bladder Cancer ◽

Controlled Trial ◽

Phase Iii ◽

Open Label ◽

Bcg Therapy ◽

Muscle Invasive ◽

Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial

European Urology ◽

10.1016/j.eururo.2018.09.005 ◽

2019 ◽

Vol 75 (1) ◽

pp. 63-71 ◽

Cited By ~ 28

Author(s):

Wei Shen Tan ◽

Anesh Panchal ◽

Laura Buckley ◽

Adam J. Devall ◽

Laurence S. Loubière ◽

...

Keyword(s):

Bladder Cancer ◽

Controlled Trial ◽

Phase Iii ◽

Invasive Bladder Cancer ◽

Open Label ◽

Muscle Invasive ◽

Re: Radiofrequency-Induced Thermo-Chemotherapy Effect versus a Second Course of bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-Muscle-Invasive Bladder Cancer following Induction or Maintenance bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-Label, Randomised Controlled Trial

The Journal of Urology ◽

10.1097/ju.0000000000000676 ◽

2020 ◽

Vol 203 (3) ◽

pp. 461-462

Author(s):

Sam S. Chang

Keyword(s):

Bladder Cancer ◽

Controlled Trial ◽

Phase Iii ◽

Invasive Bladder Cancer ◽

Open Label ◽

Muscle Invasive ◽

Re: Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial

European Urology ◽

10.1016/j.eururo.2019.01.030 ◽

2019 ◽

Vol 75 (5) ◽

pp. 879-880

Author(s):

Piotr Radziszewski ◽

Sławomir Poletajew

Keyword(s):

Bladder Cancer ◽

Controlled Trial ◽

Phase Iii ◽

Invasive Bladder Cancer ◽

Open Label ◽

Muscle Invasive ◽

Re: Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C versus bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer

The Journal of Urology ◽

10.1016/j.juro.2018.06.043 ◽

2018 ◽

Vol 200 (4) ◽

pp. 696-697

Author(s):

Sam S. Chang

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Adjuvant Treatment ◽

Controlled Trial ◽

Muscle Invasive ◽

Reply to Sławomir Poletajew, Piotr Radziszewski, Juan Palou’s Letter to the Editor re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non–Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046–52

European Urology ◽

10.1016/j.eururo.2016.06.043 ◽

2017 ◽

Vol 71 (1) ◽

pp. e31-e32

Author(s):

Tom J.H. Arends ◽

J. Alfred Witjes

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Adjuvant Treatment ◽

Controlled Trial ◽

Muscle Invasive ◽

Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non–Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046–52

European Urology ◽

10.1016/j.eururo.2018.08.045 ◽

2019 ◽

Vol 75 (2) ◽

pp. e26

Author(s):

Tom J.H. Arends ◽

J. Alfred Witjes

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Adjuvant Treatment ◽

Controlled Trial ◽

Muscle Invasive ◽

Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non–Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046–52

European Urology ◽

10.1016/j.eururo.2016.06.042 ◽

2017 ◽

Vol 71 (1) ◽

pp. e29-e30

Author(s):

Sławomir Poletajew ◽

Piotr Radziszewski ◽

Juan Palou

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Adjuvant Treatment ◽

Controlled Trial ◽

Muscle Invasive ◽

Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non–Muscle-invasive Bladder Cancer

European Urology ◽

10.1016/j.eururo.2016.01.006 ◽

2016 ◽

Vol 69 (6) ◽

pp. 1046-1052 ◽

Cited By ~ 91

Author(s):

Tom J.H. Arends ◽

Ofer Nativ ◽

Massimo Maffezzini ◽

Ottavio de Cobelli ◽

Giorgio Canepa ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Adjuvant Treatment ◽

Controlled Trial ◽

Muscle Invasive ◽

A Phase II, Open Label, Multicenter Randomised Controlled Trial Comparing Hyperthermia Plus Mitomycin To Mitomycin Alone, In Patients with Intermediate Risk Non-Muscle Invasive Bladder Cancer

http://isrctn.org/> ◽

10.1186/isrctn23639415 ◽

2014 ◽

Cited By ~ 1

Author(s):

Shriram Velamuri

Keyword(s):

Bladder Cancer ◽

Phase Ii ◽

Controlled Trial ◽

Invasive Bladder Cancer ◽

Intermediate Risk ◽

Open Label ◽

Muscle Invasive ◽